Moroccan pharmaceutical company Pharma 5 has launched the country's first 100% locally produced active pharmaceutical ingredient based on cannabis, as well as its first cannabis-based medication for severe epilepsy. The project was made possible by a 200 MDH investment and marks the culmination of a five-year research, development, and industrialization program. This achievement demonstrates Morocco's ability to transform its natural resources into high-value-added therapeutic solutions.
The cannabis-based medication is designed to treat certain severe forms of pharmacoresistant epilepsy. Pharma 5's achievement includes two major milestones: producing a 100% Moroccan active pharmaceutical ingredient based on cannabis, with over 98% purified cannabidiol, and developing a 100% Moroccan cannabis-based medication. The company's CEO, Mia Lahlou-Filali, stated that this achievement represents more than just a pharmaceutical advancement, but also reflects the company's ambition to enable Morocco to develop, produce, and master its own therapeutic solutions.
The project is based on an integrated model that combines agricultural, scientific, industrial, and pharmaceutical expertise. From regulated cannabis cultivation in the Rif region to extraction and purification of cannabidiol, Pharma 5 now controls the entire value chain of the medication, adhering to international quality, safety, and traceability standards. This project has also had a positive impact on the local economy, with 70 local families benefiting from stable and regular income.
The project has resulted in the treatment of over 10 tonnes of biomass according to pharmaceutical standards. Yasmine Lahlou-Filali, CEO and pharmacist responsible for Pharma 5 laboratories, explained that the company's goal was to transform the potential of a Moroccan natural resource into a real health solution, relying on scientific rigor and team expertise. After five years of work, the company has successfully mastered a particularly demanding process.
This achievement opens up new perspectives for research, therapeutic innovation, and the international recognition of Moroccan pharmaceutical expertise. The launch of this medication also highlights Morocco's ability to develop and produce its own therapeutic solutions, integrating the entire value chain. This project demonstrates the country's potential to become a major player in the pharmaceutical industry.
The medication is the result of a close collaboration between Pharma 5 and various institutions and stakeholders involved in the structuring of the cannabis industry in Morocco. The company's achievement is a significant milestone in the development of cannabis-based medications in the country. With this launch, Morocco is poised to make a significant contribution to the global pharmaceutical market.
The successful development of this medication has far-reaching implications for the Moroccan pharmaceutical industry and the country's economy. With its integrated model and commitment to quality and safety, Pharma 5 is well-positioned to capitalize on the growing demand for cannabis-based medications. The company's achievement serves as a model for future investments in the Moroccan pharmaceutical sector.
Key points
- Pharma 5's investment of 200 MDH in the cannabis-based medication project.
- The company's control of the entire value chain, from cannabis cultivation to medication production.
- The positive impact of the project on the local economy, with 70 families benefiting from stable income.
Reporting sources
- Pharma 5 : 200 MDH pour le premier médicament marocain à base de cannabis rifain · La Nouvelle Tribune